Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Abdel-Mannan OA, Manchoon C, Rossor T, Southin JC, Tur C, Brownlee W, Byrne S, Chitre M, Coles A, Forsyth R, Kneen R, Mankad K, Ram D, West S, Wright S, Wassmer E, Lim M, Ciccarelli O, Hemingway C, Hacohen Y; UK-Childhood Inflammatory Disease Network. Abdel-Mannan OA, et al. Among authors: coles a. Neurol Neuroimmunol Neuroinflamm. 2021 May 21;8(4):e1008. doi: 10.1212/NXI.0000000000001008. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34021056 Free PMC article.
Multiple sclerosis.
Compston A, Coles A. Compston A, et al. Among authors: coles a. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7. Lancet. 2008. PMID: 18970977 Free article.
Multiple sclerosis.
Coles A. Coles A. Pract Neurol. 2009 Apr;9(2):118-26. doi: 10.1136/jnnp.2008.171132. Pract Neurol. 2009. PMID: 19289565 Review. No abstract available.
New treatment strategies in multiple sclerosis.
Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Jones JL, et al. Among authors: coles aj. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21. Brain. 2010. PMID: 20659956 Clinical Trial.
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon beta-1a in a …
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [ …
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Hill-Cawthorne GA, et al. Among authors: coles aj. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5. J Neurol Neurosurg Psychiatry. 2012. PMID: 22056965
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
296 results